A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined with Abiraterone Acetate and Prednisone (AA-P) versus Placebo Combined with AA-P as First-Line Treatment in Patients with Metastatic Castration-Resistant Prostate Cancer

  • Voskoboynik, Mark (Primary Chief Investigator (PCI))

Project: Research

Project Details

StatusActive
Effective start/end date15/12/21 → 31/12/26

Keywords

  • Medical oncology
  • Prostate cancer
  • Clinical trial